Hagens Berman Secures $474.89M Verdict Against Takeda
A jury found Takeda Pharmaceuticals liable to the direct purchaser class for $474.89 million in damages, which will be trebled to $1.4 billion under federal antitrust law, in a class-action lawsuit over a pay-for-delay scheme involving the IBS drug Amitiza. The May 2026 verdict centered on allegations that Takeda paid a rival to delay launching a generic version of the drug by up to seven years, costing purchasers hundreds of millions in overcharges.
Attorneys representing the plaintiff class included Thomas M. Sobol (lead trial counsel), Erin C. Burns, Kristen A. Johnson, Jessica R. MacAuley, Laura Hayes, Rebekah Glickman-Simon and Daniel Polonsky of Hagens Berman. Trial paralegals included Riya Jha and Valeria Alvarez.













